Endurance RP Ltd
HKEX:575
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (9.2), the stock would be worth HK$-1.06 (269% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.4 | HK$0.63 |
0%
|
| Industry Average | 9.2 | HK$-1.06 |
-269%
|
| Country Average | 9.6 | HK$-1.11 |
-276%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| HK |
|
Endurance RP Ltd
HKEX:575
|
183.8m HKD | -5.4 | -5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 27.4 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 16.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 15.6 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 12.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 9.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.4 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 7.6 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 7.2 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.8 |
| Median | 9.6 |
| 70th Percentile | 14.9 |
| Max | 9 749.3 |
Other Multiples
Endurance RP Ltd
Glance View
Endurance RP Ltd. is an investment holding company. Along with subsidiaries, the Company operates its business through two segments. The Biopharma segment is engaged in the research, development, manufacture, marketing and sale of pharmaceutical products. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The firm is also engaged in aging research and developing artificial intelligence (AI) models and tool products related to aging research. The company offers aging and longevity clocks to the longevity clinics, preventative medicine organizations, health clubs, insurance companies, and aging research institutions.
